Company Profile

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Companyâ€™s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimerâ€™s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimerâ€™s disease (NCT03624842).

Employees

Sector

Pharmaceuticals

More about the company

10-29	Rafael Holdings Inc And Cyclo Therapeutics LLC Submit New Drug Application To FDA For Trappsol Cyclo Remibetadex For Treatment Of Niemann-Pick Disease Type C	CI
04-22	Cyclo Therapeutics Enters into Exclusive Licensing Agreement with Massachusetts Institute of Technology	CI
25-08-27	Cyclo Therapeutics Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism	CI
25-07-18	Cyclo Therapeutics, Inc. Announces Resignation of N. Scott Fine as Chief Executive Officer, Effective July 31, 2025	CI
25-06-18	Cyclo Therapeutics, Inc. Announces Continuation of Its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1	CI
25-03-27	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) dropped from S&P TMI Index	CI
25-03-26	Rafael Closes Merger With Cyclo Therapeutics	MT
25-03-26	Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals	RE
25-03-25	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) dropped from NASDAQ Composite Index	CI
25-03-24	Rafael Holdings, Inc. completed the acquisition of remaining 33.3% stake of Cyclo Therapeutics, Inc. from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC, Novit, L.P., Hercules Capital, Inc. (NYSE: HTGC) and others.	CI
25-03-06	Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings	RE
25-03-05	Cyclo Therapeutics, Inc. announced that it has received $2.5 million in funding from Rafael Holdings, Inc.	CI
25-02-07	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC(TM) Open-Label Sub-Study in Patients (< 3 Years Old)	RE

24-08-27	Maxim Downgrades Cyclo Therapeutics to Hold From Buy	MT
24-08-23	HC Wainwright Downgrades Cyclo Therapeutics to Neutral From Buy	MT
24-05-01	HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target	MT
23-09-27	Maxim Upgrades Cyclo Therapeutics to Buy From Hold With $4 Price Target	MT
23-03-20	Maxim Group Downgrades Cyclo Therapeutics to Hold From Buy	MT

25-03-26	Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals	AQ
25-02-20	CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH	BU
25-02-10	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing phase 3 TransportNPC Open-Label Sub-Study in Patients	AQ
25-02-07	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)	BU
25-01-15	Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium 2025	AQ

3 years	0.55	2.12
5 years	0.55	8.3
10 years	0.55	118

Manager	Title	Age	Since
Charles Strattan CEO	Chief Executive Officer	80	2013-09-22
Jeffrey Tate CEO	Chief Executive Officer	68	2014-07-03

Cyclo Therapeutics, Inc. Stock

Stocks

CYTH

US23254X2018

Pharmaceuticals

Latest news: Cyclo Therapeutics, Inc.

Analysts' recommendations: Cyclo Therapeutics, Inc.

Press Releases: Cyclo Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Cyclo Therapeutics, Inc.

Latest insider transactions

Other Pharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/27/25	Vivien Wong	Free	Director	25,140	0.0879%
2/27/25	Randall Toig	Free	Director	33,311	0.1164%
2/27/25	F. Ostronic	Free	Director	70,329	0.2458%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYCLO THERAPEUTICS, INC.	+1.39%	-.--%	-	-	20.73M
ELI LILLY AND COMPANY	+3.19%	+11.31%	+67.86%	+150.58%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.51%	+85.81%	658B
ABBVIE INC.	+1.41%	+3.24%	+29.22%	+107.83%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+54.15%	+67.18%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.30%	+45.62%	369B
NOVARTIS AG	+1.12%	+4.52%	+35.30%	+58.08%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.27%	+36.62%	290B
AMGEN INC.	+1.15%	+6.09%	+59.59%	+77.06%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+44.11%	+119.47%	212B
Average	+1.70%	+5.90%	+46.59%	+83.14%	473.55B
Weighted average by Cap.	+1.19%	+6.60%	+50.88%	+98.31%